Satellos Bioscience (NASDAQ:MSLE - Get Free Report) was upgraded by Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Thursday, Zacks reports.
A number of other analysts have also recently weighed in on MSLE. HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Satellos Bioscience in a report on Monday, August 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Satellos Bioscience in a research report on Wednesday, November 4th. Wall Street Zen raised shares of Satellos Bioscience from a "strong sell" rating to a "sell" rating in a research report on Saturday, November 14th. Finally, Craig Hallum assumed coverage on shares of Satellos Bioscience in a research note on Thursday, October 8th. They issued a "buy" rating and a $24.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Satellos Bioscience currently has a consensus rating of "Moderate Buy" and an average price target of $20.60.
Check Out Our Latest Research Report on MSLE
Satellos Bioscience Price Performance
Shares of NASDAQ:MSLE opened at $5.76 on Thursday. Satellos Bioscience has a 52 week low of $5.44 and a 52 week high of $13.39. The company's 50 day moving average is $7.41 and its two-hundred day moving average is $8.13.
Satellos Bioscience (NASDAQ:MSLE - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.09). As a group, research analysts forecast that Satellos Bioscience will post -1.90 earnings per share for the current year.
Institutional Trading of Satellos Bioscience
A hedge fund recently raised its position in Satellos Bioscience stock. Stonepine Capital Management LLC boosted its stake in shares of Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) by 391.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 491,624 shares of the company's stock after acquiring an additional 391,624 shares during the quarter. Satellos Bioscience comprises 0.0% of Stonepine Capital Management LLC's investment portfolio, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned 2.36% of Satellos Bioscience worth $3,723,291 as of its most recent filing with the Securities and Exchange Commission.
About Satellos Bioscience
(
Get Free Report)
Satellos Bioscience is a biotechnology company developing treatments intended to improve the body's ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company's lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Satellos Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Satellos Bioscience wasn't on the list.
While Satellos Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.